Ledipasvir

Drug Profile

Ledipasvir

Alternative Names: GS-5885

Latest Information Update: 28 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Azabicyclo compounds; Benzimidazoles; Carbamates; Fluorenes; Imidazoles; Spiro compounds
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 Aug 2015 Phase-II development is ongoing in Australia, Bulgaria, Canada, Czech Republic, Germany, Hungary, Italy, New Zealand, Puerto Rico, USA and United Kingdom
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top